BCG-medac prašak i otapalo za intravezikalnu suspenziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bcg-medac prašak i otapalo za intravezikalnu suspenziju

medac gesellschaft für klinische spezialpräparate mbh, theaterstraße 6, wedel, njemačka - bakterija bcg (bacillus calmette guérin), soj rivm (izveden iz soja 1173-p2 (živa, atenuirana)) - prašak i otapalo za intravezikalnu suspenziju - 2x10^8 do 3x10^9 vijabilnih jedinica - urbroj: nakon rekonstitucije jedna bočica sadrži: bcg (bacillus calmette guérin) bakterija mycobacterium bovis, živa, atenuirana, soj rivm izveden iz soja 1173-p2: 2x10^8 do 3x10^9 vijabilnih jedinica

BCG VACCINE SSI, prašak i otapalo za suspenziju za injekciju, Cjepivo protiv tuberkuloze (BCG), liofilizirano Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bcg vaccine ssi, prašak i otapalo za suspenziju za injekciju, cjepivo protiv tuberkuloze (bcg), liofilizirano

imunološki zavod d.d., rockefellerova 2, zagreb - cjepivo protiv tuberkuloze (bcg) cryodesiccatum - prašak i otapalo za suspenziju za injekciju - 0,75 mg (2-8 x 106 cfu) - urbroj: 1 ml rekonstituiranog cjepiva sadržava: 0,75 mg (2-8 x 106 cfu) živih, atenuiranih bakterija mycobacterium bovis (bcg), danski soj 1331

Tuberkulin PPD RT 23 SSI, 2 T.U./0,1 ml, otopina za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

tuberkulin ppd rt 23 ssi, 2 t.u./0,1 ml, otopina za injekciju

imunološki zavod d.d., rockefellerova 2, zagreb - tuberculini je produžen proteinosum pripremljena za uporabu u čovjeka - otopina za injekciju - 1 doza = 0,1 ml = 2 t.u. = 0,04 mikrograma tuberkulina ppd rt 23 - urbroj: 1 doza = 2 t.u./0,1 ml = 0,04 µg tuberkulina ppd rt 23

ROPUIDO 10 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ropuido 10 mg/1 tableta film tableta

alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - rosuvastatin - film tableta - 10 mg/1 tableta - 1 film tableta sadrži: 10 mg rosuvastatina,u obliku rosuvastatinkalcijuma

ROPUIDO 40 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ropuido 40 mg/1 tableta film tableta

alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - rosuvastatin - film tableta - 40 mg/1 tableta - 1 film tableta sadrži: 40 mg rosuvastatina,u obliku rosuvastatinkalcijuma

ROPUIDO 5 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ropuido 5 mg/1 tableta film tableta

alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - rosuvastatin - film tableta - 5 mg/1 tableta - 1 film tableta sadrži: 5 mg rosuvastatina,u obliku rosuvastatinkalcijuma

ROPUIDO 20 mg/1 tableta film tableta Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ropuido 20 mg/1 tableta film tableta

alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - rosuvastatin - film tableta - 20 mg/1 tableta - 1 film tableta sadrži: 20 mg rosuvastatina, u obliku rosuvastatinkalcijuma

Jayempi Europska Unija - hrvatski - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.